This webinar will specifically highlight high-throughput, affinity-based screening with DNA-encoded libraries, elucidation of weak or reversible small molecule–protein interactions with covalent labelling, and targeted protein degradation with bifunctional degraders. Together, these tools are accelerating the identification and development of molecules that bind and functionally alter undruggable proteins.
Who Should Attend?
John Fetter Ph.D
Product Manager, Emerging Chemical Synthesis
John received his Ph.D. in biochemistry from Michigan State University where he studied cytochrome c oxidase with Shelagh Ferguson-Miller. Then he worked in drug discovery research at North Carolina State, SmithKline Beecham, and Taxolog. After that he moved to Sigma-Aldrich, now known as Merck, where he has worked on developing assays for pharmaceutical screening. He is currently a product manager in emerging chemical synthesis where he develops products that use chemical synthesis for life science applications. Much of his focus has been on developing a portfolio of bioconjugation products. He has recently been working on making DNA-encoded libraries more accessible through their availability as off-the-shelf kits.
Research Technology Specialist
Angelo received his Ph.D in Chemistry from the University of Basel in 2017, before joining Amgen Canada for a post-doctoral position in immunology where he focused on antibody discovery. Following that, he worked on lead optimization at Selvita, a CRO company in the medicinal chemistry space – after which he moved to Merck where he works as a research technology specialist for Pharma and Biotech Research accounts.
Chemistry and synthesis
Duration: 1 hour
Presented: December 2, 2021